Incidence of Low Seroimmunity to Hepatitis B Virus in Children with Inflammatory Bowel Disease: A Single Center Experience
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Immunosuppressive therapy is frequently administered to patients with inflammatory bowel disease (IBD), which may make them more susceptible to infections like hepatitis B. Methods: A cross-sectional study was conducted on patients aged 5–18 years diagnosed with IBD who visited a gastroenterology clinic along with controls who were the same age as the patients with IBD and were healthy overall. A logistic regression analysis using the independent variables of age, sex, race, disease phenotype, surgery, and medications and the dependent variable of adequate hepatitis B surface antibody (HBsAb) titers (>10 mIU/mL) was performed on quantitative serum HBsAb titers. Results: The study enrolled 62 patients, including 37 males and 25 females. Crohn’s disease, ulcerative colitis, and indeterminate colitis were diagnosed in 16, 22, and 24 patients, respectively. Thirty-nine patients were taking corticosteroids at the time of the study, 42 were taking immunomodulators, and four were taking biologics. Compared to 44.7% of the control group, 9.3% of the patients had protective titers. Only 12 out of 62 patients had HBsAb titers greater than 10 million IU/mL. None of the patients who received biologics or corticosteroids and 3.2% of those who received immunomodulators were found to be seroimmuned. Conclusion: The younger patients had the highest titers. Patient-specific factors that may impact these low titers include the length of the patient’s illness and the use of immunosuppressants.
Abstract
Purpose: Immunosuppressive therapy is frequently administered to patients with inflammatory bowel disease (IBD), which may make them more susceptible to infections like hepatitis B. Methods: A cross-sectional study was conducted on patients aged 5–18 years diagnosed with IBD who visited a gastroenterology clinic along with controls who were the same age as the patients with IBD and were healthy overall. A logistic regression analysis using the independent variables of age, sex, race, disease phenotype, surgery, and medications and the dependent variable of adequate hepatitis B surface antibody (HBsAb) titers (>10 mIU/mL) was performed on quantitative serum HBsAb titers. Results: The study enrolled 62 patients, including 37 males and 25 females. Crohn’s disease, ulcerative colitis, and indeterminate colitis were diagnosed in 16, 22, and 24 patients, respectively. Thirty-nine patients were taking corticosteroids at the time of the study, 42 were taking immunomodulators, and four were taking biologics. Compared to 44.7% of the control group, 9.3% of the patients had protective titers. Only 12 out of 62 patients had HBsAb titers greater than 10 million IU/mL. None of the patients who received biologics or corticosteroids and 3.2% of those who received immunomodulators were found to be seroimmuned. Conclusion: The younger patients had the highest titers. Patient-specific factors that may impact these low titers include the length of the patient’s illness and the use of immunosuppressants.
참고문헌 (14)
- Shikhare G, "Inflammatory bowel disease in children : current trends", J Gastroenterol, 45, pp.673~682 (2010)
- Millonig G, "Subfulminant hepatitis B after infliximab in Crohn’s disease : need for HBV-screening?", World J Gastroenterol, 12, pp.974~976 (2006)
- Zanetti AR, "Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study", Lancet, 366, pp.1379~1384 (2005)
- Madonia S, "Occult hepatitis B and infliximab-induced HBV reactivation", Inflamm Bowel Dis, 13, pp.508~509 (2007)
- Ali T, "Viral infections in patients with inflammatory bowel disease on immunosuppressants", Am J Med Sci, 343, pp.227~232 (2012)
- Musa RB, "Hepatitis B vaccination in patients with inflammatory bowel disease", World J Gastroenterol, 20, pp.15358~15366 (2014)
- Wasan SK, "Vaccinating the inflammatory bowel disease patient : deficiencies in gastroenterologists knowledge", Inflamm Bowel Dis, 17, pp.2536~2540 (2011)
- Watts A, "Incidence of low seroimmunity to hepatitis B virus in children with inflammatory bowel disease", J Pediatr Gastroenterol Nutr, 65, pp.551~554 (2017)
- Moses J, "Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab", Am J Gastroenterol, 107, pp.133~138 (2012)
- Musa RB, "Hepatitis B vaccination in patients with inflammatory bowel disease. World journal of gastroenterology", World J Gastroenterol, 20, pp.15358~15366 (2014)
- Jiang H, "Immune response to hepatitis B vaccination among people with inflammatory bowel diseases : a systematic review and meta-analysis", Vaccine, 35, pp.2633~2641 (2017)
- Belle A, "Impact of immuno-suppressive therapy on hepatitis B vaccination in inflammatory bowel diseases", Eur J Gastroenterol Hepatol, 27, pp.877~881 (2015)
- Andrade P, "Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients", J Gastroenterol Hepatol, 30, pp.1591~1595 (2015)
- Bruce MG, "Antibody levels and protection after hepatitis B vaccine : results of a 30-year follow-up study and response to a booster dose", J Infect Dis, 24, pp.16~22 (2016)